Korea Investment Corp Intellia Therapeutics, Inc. Transaction History

Korea Investment Corp

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$11.39 - $27.13 $661,759 - $1.58 Million	-58,100 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$25.78 - $32.6 $247,488 - $312,960	-9,600 Reduced 14.18%	58,100 $1.66 Million
Q2 2018 Aug 13, 2018	BUY	$20.02 - $30.79 $1.36 Million - $2.08 Million	67,700 New	67,700 $0

317

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $835M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Korea Investment Corp, based on Form 13F filings with the SEC.

Stay updated on Korea Investment Corp with notifications on news.